Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems, Inc. (NASDAQ: MMSI) delivers essential updates for stakeholders tracking innovations in minimally invasive medical devices. This dedicated news hub provides verified information about the company's advancements in cardiology, radiology, and vascular access technologies.
Investors and healthcare professionals will find timely updates on regulatory milestones, product launches, and strategic initiatives. Our curated collection includes earnings reports, clinical trial developments, and partnership announcements that shape Merit Medical's position in the $450B+ global medical device market.
Key coverage areas include new FDA clearances for diagnostic catheters, financial performance across international markets, and innovations in embolization technologies. All content undergoes strict verification to ensure compliance with financial reporting standards and medical industry regulations.
Bookmark this page for direct access to Merit Medical's latest developments in interventional radiology tools, quarterly financial disclosures, and executive leadership updates. For real-time alerts on critical announcements, subscribe to our validated news feed.
Merit Medical (NASDAQ: MMSI) signed a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, a PENTAX Medical subsidiary, with closing expected in Q4 2025. Total consideration is $22 million ($19 million cash at closing plus up to $3 million contingent).
Merit expects the assets to contribute ~$1 million revenue from a projected Nov 1–Dec 31, 2025 closing, and to add approximately $6–8 million revenue for the twelve months ending Dec 31, 2026. The company said the deal will initially be dilutive to 2025 and 2026 earnings but is projected to be accretive thereafter.
PENTAX Medical announced on October 15, 2025 an asset purchase agreement selling the C2 CryoBalloon™ technology to Merit Medical Systems (NASDAQ: MMSI). The C2 CryoBalloon, part of PENTAX Medical's therapeutic portfolio since 2017, provides controlled cryotherapy for Barrett's Esophagus and related GI disorders.
Under the agreement, Merit will integrate C2 into its Endoscopy portfolio, transfer product manufacturing to its facility in South Jordan, Utah, and hire several PENTAX Medical employees to support continuity. PENTAX Medical said the sale lets it sharpen focus on its core business of flexible reusable endoscopy and deepen clinical partnerships.
Merit Medical Systems (NASDAQ: MMSI) will report third quarter 2025 results for the period ended September 30, 2025 after market close on Thursday, October 30, 2025.
The company will host an investor conference call the same day at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, 2:00 p.m. Pacific). Investors must pre-register for dial-in details; a live webcast and slide deck will be available on Merit’s investor website at www.merit.com. The press release lists media and investor contacts and notes Merit employs approximately 7,400 people and has a sales and clinical support team totaling more than 800 worldwide.
Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT® Radar Localization technology, which has now been used to treat 750,000 patients worldwide. The wire-free, non-radioactive localization system helps physicians precisely target and remove abnormal breast tissue with accuracy of +/- 1mm.
The company recently introduced SCOUT MD™, a next-generation system featuring four distinct reflector shapes for improved tumor margin mapping. SCOUT technology has been implemented in over 1,100 facilities across 50 countries, with more than 500 cases performed daily and approximately 10,000 cases monthly. The system has been featured in over 100 clinical publications covering nearly 8,500 patients.
Merit Medical Systems (NASDAQ: MMSI) has received CE Mark approval for its Embosphere® Microspheres for use in genicular artery embolisation (GAE) to treat knee osteoarthritis in the European Union. This expanded indication targets a significant market, as osteoarthritis affects approximately 595 million people globally, with the knee being the most commonly affected joint.
Clinical data demonstrates that over 75% of patients treated with Embosphere for GAE achieved clinical success with significant pain reductions sustained through 24 months. The treatment showed superior results compared to corticosteroid injections, with greater improvements in pain and quality of life at 3 months. Embosphere has been used to treat more than 800,000 patients worldwide and has been studied in over 130 pivotal clinical articles over its 25-year history.
Merit Medical Systems (NASDAQ: MMSI) has announced the enrollment of the first patient in its WRAP North America registry study at Bluff City Vascular in Memphis, TN. The registry will evaluate the real-world safety and effectiveness of the WRAPSODY Cell-Impermeable Endoprosthesis (CIE), a device designed to restore vascular access in hemodialysis patients.
The study aims to enroll up to 250 patients across the US and Canada, following them for three years. This registry complements the ongoing WRAP Global registry, which targets 500 non-North American patients. The WRAPSODY CIE received FDA approval in December 2024 and Health Canada approval in April 2025, following earlier approvals in the EU and Brazil.
Merit Medical Systems (NASDAQ: MMSI) has launched the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology in the US market. This innovative medical device offers significant improvements over competing products, including twice the lubricity, twice the resistance to buckling and kinking, and 40% less insertion force.
The device addresses critical challenges in radial access procedures, where radial artery spasm occurs in up to 20% of patients and arterial occlusion affects approximately 4.6% of cases. The SnapFix technology provides twice the adhesive strength compared to leading competitors, with superior physician ratings for performance and ease of use.
Merit Medical Systems (NASDAQ:MMSI) reported strong Q2 2025 financial results, with revenue reaching $382.5 million, up 13.2% year-over-year. The company demonstrated solid performance with constant currency revenue growth of 12.5% and organic growth of 6.7%. Notable metrics include non-GAAP EPS of $1.01 (up 9.8%) and free cash flow generation of $89.1 million in H1 2025.
The company has raised its full-year 2025 guidance, now expecting revenue between $1.495-$1.507 billion (10-11% growth) and non-GAAP EPS of $3.52-$3.72. Additionally, Merit announced the acquisition of Biolife, a hemostatic devices manufacturer, and appointed Martha Aronson as new President and CEO, effective October 3, 2025.
Merit Medical Systems (NASDAQ: MMSI) has appointed Martha Aronson as its new President and CEO, effective October 3, 2025. Founder Fred Lampropoulos will transition from his current role as President and CEO to continue serving as Chairman of the Board. Aronson brings extensive healthcare experience, having managed global businesses worth $500M-$1B at companies including Ecolab and Hill-Rom.
Additionally, Merit announced preliminary Q2 2025 revenue of $380-384 million, representing a 12-14% increase year-over-year. On a constant currency basis, revenue grew 11-13%. The company will release complete Q2 2025 financial results on July 30, 2025.
Merit Medical Systems (NASDAQ: MMSI), a leading healthcare technology manufacturer, has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host an investor conference call the same day at 5:00 p.m. Eastern Time.
Founded in 1987, Merit Medical specializes in proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. The company maintains a global presence with over 800 sales and clinical support professionals and approximately 7,300 employees worldwide.
FAQ
What is the current stock price of Merit Med Sys (MMSI)?
What is the market cap of Merit Med Sys (MMSI)?
